# A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.

> **NCT03540524** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 10 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** GLPG2451 dose regimen A
- **DRUG:** GLPG2451 dose regimen B
- **DRUG:** GLPG2222
- **DRUG:** GLPG2737

## Key facts

- **NCT ID:** NCT03540524
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-31
- **Primary completion:** 2019-03-11
- **Final completion:** 2019-03-11
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03540524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03540524, "A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03540524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*